Kiora Pharmaceuticals (KPRX) Institutional Ownership → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free KPRX Stock Alerts $0.71 +0.09 (+14.61%) (As of 03/28/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Kiora Pharmaceuticals (NASDAQ:KPRX)CurrentInstitutional OwnershipPercentage76.97%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$321,862.03Number ofInstitutional Sellers(last 12 months)0 Get KPRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Kiora Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data KPRX Institutional Buying and Selling by Quarter Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> Kiora Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/15/2024Citadel Advisors LLC92,585$49K0.0%N/A1.204% 8/15/2023Walleye Capital LLC250,258$0.16M0.0%N/A12.365% 5/12/2023Dimensional Fund Advisors LP12,254$41K0.0%N/A0.607% 5/11/2023Acadian Asset Management LLC21,460$70K0.0%N/A1.062% 2/15/2023Boothbay Fund Management LLC11,679$40K0.0%N/A1.024% 11/15/2022BlackRock Inc.14,462$89K0.0%-31.1%1.269% 5/13/2022Renaissance Technologies LLC93,619$58K0.0%N/A0.739% 5/13/2022Vanguard Group Inc.77,010$48K0.0%-49.2%0.608% (Data available from 1/1/2016 forward) KPRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KPRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Kiora Pharmaceuticals shares: Walleye Capital LLC ($0.16M), BlackRock Inc. ($89K), Acadian Asset Management LLC ($70K), Renaissance Technologies LLC ($58K), Citadel Advisors LLC ($49K), Vanguard Group Inc. ($48K), and Dimensional Fund Advisors LP ($41K).Learn more on KPRX's institutional investors. What percentage of Kiora Pharmaceuticals stock is owned by institutional investors? 76.97% of Kiora Pharmaceuticals stock is owned by institutional investors. Learn more on KPRX's institutional investor holdings. Which institutional investors have been buying Kiora Pharmaceuticals stock? The following institutional investors have purchased Kiora Pharmaceuticals stock in the last 24 months: Walleye Capital LLC ($0.25M), Renaissance Technologies LLC ($93.62K), Citadel Advisors LLC ($92.59K), Acadian Asset Management LLC ($21.46K), Dimensional Fund Advisors LP ($12.25K), and Boothbay Fund Management LLC ($11.68K). How much institutional buying is happening at Kiora Pharmaceuticals? Institutional investors have bought a total of 481,855 shares in the last 24 months. This purchase volume represents approximately $2.69M in transactions. Which Kiora Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Kiora Pharmaceuticals stock in the last 24 months: Vanguard Group Inc. ($74.69K), and BlackRock Inc. ($6.52K). How much institutional selling is happening at Kiora Pharmaceuticals? Institutional investors have sold a total of 81,211 shares in the last 24 months. This volume of shares sold represents approximately $1.90M in transactions. Related Companies: Tharimmune Institutional Ownership PaxMedica Institutional Ownership GeoVax Labs Institutional Ownership Lipella Pharmaceuticals Institutional Ownership Artelo Biosciences Institutional Ownership Virpax Pharmaceuticals Institutional Ownership Kazia Therapeutics Institutional Ownership Genprex Institutional Ownership Lixte Biotechnology Institutional Ownership Exicure Institutional Ownership This page (NASDAQ:KPRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.